As the COVID-19 pandemic continues to spread across the globe, NCGS continues to face these challenges to address study conduct continuity. Quarantine and restricted travel are among these challenges. Our number one priority remains focused on the health and safety of participants, site staff, and monitoring personnel involved in these trials.  We strive to maintain the integrity of the work we do for each and every Sponsor.

In accordance with our own Business Continuity plan, following updates and guidelines from global regulatory agencies, NCGS has expanded our Remote Data Review and Remote Source Data Verification Guidelines to effectively continue in-process and future clinical trials.

Our response to the current global crisis addresses, but not limited to, the following:

  • Subject Compliance and Safety
  • Data Integrity
  • Risk Mitigation and Management
  • Source Data Access
  • Telehealth
  • Home Health Visits
  • Expanded Remote and Centralized Monitoring
  • Drug Accountability
  • Regulatory Guidance Updates

NCGS continues to face challenges with achievable solutions to ensure that we continue to deliver highest standards of quality, data integrity, and monitoring that our Sponsors are accustomed to. We continue to monitor areas of disruption or risk and implement actionable plans to safeguard patient safety, data integrity and business continuity throughout all trials.

Our promise is to make every effort to mitigate the threat to timeliness and excellence of our trials. In the meantime, we send our best wishes to you and your loved ones during these challenging times. Please feel free to contact us with any questions.


Nancy C. G. Snowden

Founder and CEO